Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net ProfitGlobeNewsWire • Thursday
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research CollaborationGlobeNewsWire • 08/27/24
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)GlobeNewsWire • 07/15/24
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)GlobeNewsWire • 07/12/24
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 06/06/24
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024GlobeNewsWire • 05/31/24
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/18/24
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024GlobeNewsWire • 04/11/24
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological DisordersGlobeNewsWire • 04/03/24
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.GlobeNewsWire • 01/31/24